Skip Main Navigation

Programme Overview

This programme has been awarded 12 CME credits by the European Society for Medical Oncology.
The Accreditation Council of Oncology in Europe (ACOE) has also appraised and approved the conference programme. ACOE credits have been endorsed by the European Accreditation Council for Continuing Medical Education (EACCME) — a body of the European Union of Medical Specialists (UEMS).
ESMO logo ACOE ECCO logo

Friday, November 12, 2010

07:30-08:30 Workshop on Clinical Trial Design - John A "Drew" Ridge
08:50-09:00 Welcome - Jim Bonner
9:00-09:50 Opening keynote lecture (moderator: Jim Bonner)
  HPV-associated cancers on the rise, a growing problem? - Margaret Stanley
09:50-10:20 Coffee break
10:20-12:00 Joint session (moderator: Margaret Stanley)
HPV vaccines: current issues in HPV-associated cancers
10:20 Screening women vaccinated for HPV16/18 - Jack Cuzick
10:45 Vaccination for boys: the paediatrician's perspective - Hal Jenson
11:10 Community randomised Phase IV HPV vaccination effectiveness trial: Baseline characteristics and trial deliverables - Matti Lehtinen
11:35 Vaccine development in the developing world - John Sellors
12:00 Session ends
12:00-13:30 Lunch break
13:30-15:10 Parallel session (moderator: Chris Meijer)
  Risk assessment and treatment in cervical cancer
13:30 Management of screen-detected HPV-positive women- Guglielmo Ronco
13:55 Risk of high-grade CIN in women with HPV infection: role of persistence and genotyping - Nicolas Wentzensen
14:20 Organisation of HPV-based screening - Ahti Anttila
14:45 Age issues in HPV screening - Guglielmo Ronco
15:10 Session ends
13:30-15:10 Parallel session (moderator: Maura Gillison)
  New agents in head and neck cancer
13:30 HPV and incidence trends for head and neck cancer - Anil Chaturvedi
13:55 The new era of targeted agents in head and neck cancer - Jim Bonner
14:20 Side effects of the new targeted agents in head and neck cancer - Jean Pierre Armand
14:45 Critical assessment of the role of chemotherapy, surgery, and radiation therapy in HPV-related oropharyngeal cancer and future clinical trials - Marshall Posner
15:10 Session ends
15:10-15:40 Tea break
15:40-17:20 Joint session (moderator: Marshall Posner)
  Clinical trial design in relation to HPV-associated disease
15:40 HPV and clinical trial design for head and neck cancer - Maura Gillison
16:05 The importance of window of opportunity studies - Jan Vermorken
16:30 Long-term efficacy of HPV vaccination against hard end-points: Cancer registry based follow-up of phase III efficacy trials - Jorma Paavonen
16:55 Ecological competition of vaccine-type and non-vaccine-type HPVs before and after mass vaccination - Matti Lehtinen
17:20 Session ends
17:20 End of day

Saturday, November 13, 2010

9:00-10:40 Parallel session (moderator: Jorma Paavonen)
  HPV testing, translational research, and the clinic
09:00 HPV testing in the developing world - John Sellors
09:25 Use of biomarkers in HPV screening programmes - Nicolas Wentzensen
09:50 Is HPV prognostic, predictive, or both? - Lisa Licitra
10:15 Therapeutic HPV vaccines - Cornelia Trimble
10:40 Session ends
9:00-10:40 Parallel session (moderator: Jens Overgaard)
  Management of mouth and oral-pharyngeal cancers in relation to HPV
09:00 Prevalence, natural history, and transmission of oral HPV in relation to oropharyngeal cancer- Gypsyamber Dsouza
09:25 HPV-specific genetic markers in HPV-associated head and neck and cervical cancers- Peter Snijders
09:50 Neck dissection in the surgical management of oropharyngeal cancer: controversies and outstanding questions - Ian Martin
10:15 Evolving treatment paradigms in the management of oropharyngeal cancer - Maura Gillison
10:40 Session ends
10:40-11:10 Coffee break
11:10-12:25 Joint session (moderator: Joel Palefsky)
  Genetics, environment, and lifestyle factors
11:10 HPV infection in pregnancy: issues in relation to prophylactic and therapeutic strategies - Jorma Paavonen
11:35 Co-morbidity and smoking behaviour in HPV positive and negative HNSCC patients in relation to outcome - Jens Overgaard
12:00 Race and ethnicity in HPV-related oropharyngeal cancer - Kevin Cullen
12:25 Session ends
12:25-14:00 Lunch break
14:00-15:15 Parallel session (moderator: Guglielmo Ronco)
  Penile and anal cancers: biology and current management
14:00 Prevention and treatment approaches to AIN and anal cancer - Joel Palefsky
14:25 Prophylactic vaccines for anogenital cancer - Margaret Stanley
14:50 Circumcision for prevention of ano-genital and oral cancers? - Tim Oliver
15:15 Session ends
14:00-15:15 Parallel session (moderator: Jean Pierre Armand)
  Radiation in HPV-infected head and neck and oral-pharyngeal cancers
14:00 Radiation in HPV-infected head and neck and oral pharyngeal cancers - Pernille Lassen
14:25 Rationale for radiation dose reduction in HPV-related oropharyngeal cancer - Marshall Posner
14:50 Hypoxia, HPV, and radiotherapy: interactions and implications for outcome - Jens Overgaard
15:15 Session ends
15:20-16:10 Closing keynote lecture (moderator: Jim Bonner)
  HPV infection in the HIV-positive host: molecular interactions and clinical implications - Joel Palefsky
16:10-16:20 Closing remarks - Jim Bonner

Programme is correct at time of publication

Advertisement